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Abstract
Introduction: Endometrial cancer is the second most common gynecological tumor. There is still no recom-
mended screening method for endometrial cancer. The application of transvaginal sonography, hysteroscopy 
and Pap test may prove useful in screening for this disease. Atypical glandular cells represent an important 
finding in Pap tests and they are related to histopathological verification of the endometrium. The aim of the 
study was to determine the usefulness of the Pap test in assessing the cervical infiltration, as well as to de-
termine the significance of hormonal status and histopathological type of tumor in a pathological Pap test in 
patients with endometrial cancer. 
Methods: The study was retrospective. The analysis included the data obtained from 62 operated patients 
diagnosed with enometrial cancer, medical history (menopausal status), histopathological findings after sur-
gery (type and stage of the disease) and a preoperative Pap smear. The chi squared and Fisher’s test were 
used. 
Results: The difference in the prevalence of pathological Pap test in premenopausal and postmenopausal 
group of patients was not statistically significant. The difference in the prevalence of pathological Pap test in 
the group of endometrioid and non-endometrioid tumours of the uterine corpus had statistical significance. 
The difference in the prevalence of pathological Pap test compared to the present stage (I and II) was not 
statistically significant. 
Conclusion: Pap smear does not correlate with menopausal status in women with endometrial carcinoma. 
Abnormal Pap test is more commonly found in cases of non-endometroid tumours. Pap smears cannot be 
used to assess cervical involvement. © 2011 All rights reserved
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Introduction
Endometrial carcinoma makes up 3.9% of all ma-
lignant tumors among women (200.000 patients) 
and 1.7% of all deaths (50.000) caused by malig-
nant diseases. The rate of incidence increases with 
age. The incidence increases begins 5-10 years be-
fore menopause and the peak is reached at about 
65-70 years of age (2). There is still no recommend-
ed screening test for endometrial cancer. The Pap 
test is not a routine in the diagnosis of endome-
trial abnormalities. Most authors believe that the 
cytological diagnosis is not sufficiently sensitive in 
the detection of endometrial cancer (3). Cytology 
has low sensitivity due to anatomical reasons – cell 
desquamation must pass through the cervical ca-
nal and is thereby subject to degenerative changes. 
Cervical canal stenosis and reduced number of 
cells in the smear are common after menopause (3). 
The cytological sampling of the endometrium can 
be direct: from the uterus (including aspiration, 
brushing, rinsing), and indirect: the sampled cells 
are obtained from spontaneous desquamation 
through the cervical canal (4). Indirect tests are un-
reliable and cytologists encounter diagnostic diffi-
culties in differentiating normal from abnormal en-
dometrial cells, whereas direct tests are expensive 
and invasive and are only recommended for wom-
en at high risk of developing endometrial cancer (5).
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Atypical glandular cells are unusual but they rep-
resent an important finding in a Pap smear (6). 
The Bethesda system classifies atypical glandular 
cells (AGUS) as glandular cells with some degree 
of nuclear atypia, but which do not have the fea-
tures of malignant carcinoma cells. The AGUS 
are present in 0.18 to 0.74% of all Pap smears. 
An important percentage of these patients has 
severe endometrial pathology, and these find-
ings require a serious evaluation (6,7,8,9). The 
presence of an atrophic smear, greater than 
twice the size of an intermediate cell nucleus and 
the absence of clusters with irregular borders 
help in identifying endometrial carcinoma (7). 
Liquid-based Pap test can be useful in the di-
agnosis of endometrial carcinoma. The ap-
plication of this test helps detect endome-
trial carcinoma with high sensitivity (10).
The combination of cytological diagnosis, trans-
vaginal ultrasound and hysteroscopy may be useful 
in selecting the patients who need to undergo his-
topathological sampling of endometrial tissue (11). 
The aim of the study was to determine the use-
fulness of the Pap test in assessing the cervi-
cal infiltration, as well as to determine the 
significance of hormonal status and histo-
pathological type of tumor in a pathological 
Pap test in patients with endometrial cancer.
Methods
Samples
The study was retrospective and it included pa-
tients who had received surgical treatment for 
histopathologically verified endometrial cancer. 
There were 62 patients diagnosed with endometri-
al cancer. The analysis included the Pap test, medi-
cal history (menopausal status), histopathological 
reports after surgery and post-operative stage. The 
Pap test results were observed in relation to meno-
pausal status, histological type and stage of tumor. 
Statistical analysis
Comparison of the frequency of attribute char-
acteristics between groups was performed with 
the chi square test or Fisher’s exact probabil-
ity test of the null hypothesis when expected fre-
quency of some features was less than five. The 
statistical analysis was performed using SPSS 
software and p<0.05 was considered significant.
Results
The research included 62 patients diagnosed with 
endometrial cancer. Pap test made during diag-
nostic procedures or preparation for surgical treat-
ment was analyzed. There were 5 (8%) premeno-
pausal patients and 57 (92%) postmenopausal 
patients. All premenopausal patients had normal 
Pap smears. Among the postmenopausal patients 
there were 12 cases (19.4%) of abnormal Pap 
smears. There was no difference in the presence of 
pathological Pap smear in premenopausal or post-
menopausal groups of women (P = 0.257) (Table 1).
In the study group (62 patients) there were 54 reg-
istered endometrioid types of tumor and 8 non-
endometrioid types of tumor. The comparison of 
the patients with endometrioid and non-endo-
metrioid types of tumors revealed that abnormal 
Pap test results were present in 10 (18.5%) pa-
tients with endometrioid type of tumor, whereas 
in non-endometrioid tumor type there were 2 
patients (24%) with abnormal Pap test results 
( χ 2 = 6.92, p = 0.031). (The difference in find-
ings between the groups was statistically signifi-
cant). Abnormal Pap test was significantly more 
common in non-edometrioid tumors. (Table 2).
Pap test was compared with the determined histo-
pathological stage of the disease where the materi-
al was removed surgically. In patients with an early 
stage of the disease, a normal Pap test was present 
in 89.7% and 10.3% in pathological cases, while in 
patients with other disease stages, a normal Pap 
character-
istics
Menopause total compari-son
no (n=5) Yes (n=57) (n=62)
p=0.257
Pap smear
normal 5 (100.0%) 45 (78.9%) 50 (80.6%)
Pathological - 12 (21.2%) 12 (19.4%)
Table 1.  Menopause and Pap tests ratio
characteristics non-endometri-oid type (n=8)
endometrioid 
type (n=54) comparison
Pap smear
χ2=6.92; 
p=0.031normal 6 (75.0%) 44 (81.5%)
Pathologic 2 (25%) 10 (18.5%)
Table 2.  relationship between Pap smear testing and hp-
type endometrial cancer
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test was found in 72.2% and abnormal in 27.8% 
of cases. Fisher's test did not confirm significant 
differences in the prevalence of individual findings 
of the Pap test for women with first and second 
stage of the disease (p> 0.005). Involvement of the 
cervix cannot be detected by Pap smears (Table 3).
Discussion
In our study pathological Pap smear was registered 
only in postmenopausal patients but this differ-
ence was not statistically significant. According to 
data (Bethesda 2001), the occurrence of endome-
trial cells in cervical cytology in women over 45 is 
often associated with endometrial cancer and en-
dometrial hyperplasia (12), but other authors sug-
gest that hormonal status is not relevant in terms 
of abnormal glandular cells in Pap smear (13). A 
comparison of the results of the Pap test revealed 
that abnormal Pap smears were significantly more 
frequent in a group of women with tumors with 
non-endometrioid histology. These tumors show 
more rapid progression, deeper myometrial in-
volvement, more frequent lymphovascular in-
vasion and cervical involvement (14). Cytology 
cannot be used as an independent method, but in 
combination with transvaginal ultrasound (TVS) 
it can be performed for patients with unfavorable 
hp types and cervical involvement. (3, 4, 5). Ska-
znik et al. (15) state that the unfavorable endome-
trial types of cancers had frequent abnormal Pap 
smears. The stages of endometrial cancer are based 
on examination of tissue removed during an op-
eration. Compared to earlier clinical staging, this 
method has an advantage. Most authors believe 
that surgical staging is reliable, particularly in the 
case of adverse findings of hp, in the case of cervi-
cal involvement and deep myometrial infiltration 
(15, 16, 17). Cervical infiltration has a worse prog-
nosis, increases the incidence of metastases and 
local recurrence (18). In our research, Pap test re-
sults for patients with the disease in an early stage 
were normal in 89.7% of cases and abnormal in 
10.3% of cases. On the other hand, Pap test results 
for patients with the disease in other stages were 
normal in 72.2%, and abnormal in 27.8% of cases. 
Fisher’s test did not confirm significant differences 
in the prevalence of individual findings of the Pap 
test for women with first and second stage of the 
disease (p> 0.005). Involvement of the cervix can-
not be detected by Pap test. Imaging methods may 
be applied in the evaluation of cervical involve-
ment (19, 20). Other authors suggest that Pap 
smear is not suitable for the assessment of cervi-
cal infiltration in patients with endometrial carci-
noma. The exceptions are patients with tumors of 
low grade endometrioid type, where a normal Pap 
smear indicates a very low risk of cervical involve-
ment and low risk of lymph node metastasis (21). 
Conclusion
Patients with endometrial cancer may have ab-
normal Pap smears regardless of hormonal sta-
tus. If non-endometrioid type of tumor is pres-
ent, abnormal Pap test is more common. Cervical 
involvement cannot be estimated by Pap tests.
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Pap smear findings
Disease stage
comparison
i ii
normal 35 (89.7%) 13 (72.2%)
p=0.123
abnormal 4 (10.3%) 5 (27.8%)
total 39 (100.0%) 18 (100.0%)
Table 3.  relationship between the stage and the Pap test.
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